At its meeting on 08 August 2022 the Transparency Council adopted Opinion No. 123/2022 on the changes to the drug programme B.82 “Treatment of patients with the active form of spondyloarthritis (SpA) without radiographic changes characteristic of AS (ICD-10: M46.8)”.
Publication with the minutes of the Transparency Council meeting